

1 **Title**

2 "A Randomized Placebo Controlled Clinical Trial of a Metabolic Shifting Probiotic,
3 Sugar Shift, for the Treatment of T2DM"

4 Authors: Gissel García^{1a}, Josanne Soto^{1b}, Lays Rodríguez^{1c}, Maricela Nuez^{1d}, Noraika
5 Domínguez^{1d}, Emilio F. Buchaca^{1c}, Duniesky Martínez², Rolando J. Gómez^{1b},
6 Yohanka Ávila^{1c}, Martha R. Carlin³, Raúl J. Cano^{3, 4*}.

7 **Affiliations:**

8 ^{1a} Pathology Department, Clinical Hospital Hermanos Ameijeiras (HHA). Calle San
9 Lázaro No 701, Esq.a Belascoaín, Centro Habana, La Habana, P.C. 10400, Cuba.

10 ^{1b} Clinical Laboratory Department, Clinical Hospital Hermanos Ameijeiras (HHA). Calle
11 San Lázaro No 701, Esq.a Belascoaín, Centro Habana, La Habana, P.C. 10400, Cuba.

12 ^{1c} Internal Medicine Department, Clinical Hospital Hermanos Ameijeiras (HHA). Calle
13 San Lázaro No 701, Esq. a Belascoaín, Centro Habana, La Habana, P.C. 10400, Cuba.

14 ^{1d} Endocrinology Department, Clinical Hospital Hermanos Ameijeiras (HHA). Calle San
15 Lázaro No 701, Esq.a Belascoaín, Centro Habana, La Habana, P.C. 10400, Cuba.

16 ² Research and Development Department. Center for Genetic Engineering and
17 Biotechnology of Sancti Spíritus (CIGBSS),. Circunvalante Norte S/N, Olivos 3,
18 Apartado Postal 83, Sancti Spíritus, P.C 60200, Cuba.

19 ³ The BioCollective, LLC, 5650 N. Washington St, Suite C9, Denver, Co 80216

20 ⁴ Biological Sciences Department, California Polytechnic State University, San Luis
21 Obispo, CA 93407 USA

22

23 *Corresponding author and address: 1854 Castillo Court, San Luis Obispo, CA 93405

24 USA;

25 Tel: +1 (805) 748-9717; E-mail: rcano@calpoly.edu

26

27 **Abstract**

28 Type 2 diabetes mellitus (T2DM) is a chronic metabolic disorder characterized by
29 hyperglycemia, insulin resistance and chronic inflammation. Probiotics have been
30 claimed effective in the management of obesity and type 2 diabetes mellitus.

31 BiotiQuest™ Sugar Shift is a symbiotic formulation rationally designed for the
32 endogenous conversion of glucose and fructose to support restoration of the human
33 gut microbiota, modulation of intestinal glucose, and the production of anti-
34 inflammatory metabolites.

35 We report the results of a 12-week, double blind, placebo-controlled study designed to
36 evaluate Sugar Shift in Cuban T2DM patients. Clinical parameters, including fasting
37 and 2h post-prandial glucose, hemoglobin A1c, a lipid panel, insulin, creatinine, and
38 serum lipopolysaccharide levels were assessed. Microbiome composition was
39 assessed by 16S amplicon sequencing of the variable region V3-V4 of the 16S rRNA
40 gene. Metabolic biomarkers were inferred from microbiome data by Kruskal-Wallis H
41 test and LEfSe.

42 Fasting glucose, Insulin, and serum LPS levels decreased significantly at day 84 as
43 compared to day 1 in the treated group and to control group. Hb A1c remained stable
44 in the treatment group as compared to the controls but not show significant
45 improvement in the study period.

46 Microbiome analysis showed significant increase in Chao1 alpha diversity in the
47 treated group between day 1 and day 84. Taxonomic and functional biomarkers
48 revealed significant differences between the Day 1 and Day 84 microbiome profiles in

49 the treatment group, primarily associated with acetate, propionate, and butyrate
50 production.

51 Our results indicate that Sugar Shift can be a suitable adjunct therapy to standard of
52 care therapy in the management of T2DM based upon the improvement in key
53 inflammatory and insulin resistance markers. These results were interpreted as an
54 indication of favorable microbiome changes during the course of the treatment for 12
55 weeks.

56

57 Introduction

58 Diabetes mellitus (DM), is a metabolic disease characterized by alterations in glucose
59 metabolism (1). Four main etiological categories are described: type 1 (T1DM), type 2
60 (T2DM), seasonal DM and the other types of DM, which fall into the same etiological
61 category. T2DM comprises 90% of all cases (1). Statistics from 2018 show that this
62 metabolic condition affected 537 million individuals worldwide
63 (<https://idf.org/aboutdiabetes/what-is-diabetes/facts-figures.html>) and it is estimated
64 that by 2045, about 625 million people will suffer from this disease (2). Cuba does not
65 escape this situation; in the Statistical Yearbook of the Ministry of Public Health
66 (MINSAP) of 2019, a prevalence of this disease of 66.7% was reported, 2% higher than
67 that reported in 2018 (3). Therefore, diabetes mellitus in general, and type 2 in
68 particular, is considered an emerging pandemic disease by the international scientific
69 community, since its prevalence increases in all countries regardless of their level of
70 development (4).

71 T2DM is diagnosed when there is a state of glucose intolerance (glucose \geq
72 11.1mmol/L) and fasting elevated blood sugar levels (\geq 7mmol/L or 126 mg/dl) are
73 detectable. (1, 5). Treatment requires lifestyle change, timely incorporation of oral
74 antidiabetics, including metformin, and maintaining of glycosylated hemoglobin
75 (HbA1c) at levels below 7%. However, in clinical practice, patients do not always
76 achieve glycemic control (4).

77 It is proposed that genetic and environmental factors are associated with the
78 development of this etiological category (1, 6). In the context of these factors, the gut

79 microbiota plays a central role in this disease as it is able to modify the biological and
80 metabolic functions of the organism, regulate inflammation and as is essential for the
81 mechanisms of innate and adaptive immunity (7).

82 Disease severity, immunodeficiencies, obesity and insulin resistance have been
83 associated with imbalances in the gut microbiota. This phenomenon, known as
84 dysbiosis, occurs from multiple causes (4). These include unbalanced diets (8),
85 environmental toxin exposures (9, 10) and the indiscriminate use of antibiotics (11, 12),
86 among other factors that have been associated with the pathogenesis of T2DM (13-
87 15). A diet rich in carbohydrates and processed foods favors the reduction of beneficial
88 bacteria and the growth of others that, for example, increase the secretion of
89 lipopolysaccharides (LPS). Increased secretion of LPS induces insulin resistance (1, 4,
90 7).

91 Recent studies support that the consumption of certain formulations of beneficial
92 bacteria in association with the nutrients they produce could reshape the intestinal
93 microbiota and, in this way, improve glucose levels and insulin resistance in individuals
94 suffering from T2DM (16). This group of living microorganisms, administered to a host
95 in appropriate forms and quantities, improves or restores the intestinal microbiota and,
96 consequently, its metabolic and immunological functions. For this reason, these
97 organisms have been referred to as probiotics. These mixtures are administered as a
98 symbiotic formulation with prebiotics and non-digestible plant fibers that stimulate the
99 growth of the probiotic organisms and other beneficial intestinal microorganisms (16,
100 17).

101 There are many commercial probiotic formulations on the market which mostly
102 comprise a limited variety of commercial probiotic strains in wide use. However, many
103 are not balanced formulations and there is very little strain or species diversity in the
104 currently commercialized products. Many formulas do not contain any prebiotic at all
105 and most do not evaluate or show the analysis of the genetic and metabolic profile of
106 the consortium of bacteria as a working community in the formula. The BiotiQuest™
107 Sugar Shift (Sugar Shift) preparation, on the other hand, is a formulation designed with
108 the aid of a community-based flux balance analysis model (18, 19), coined the
109 BioFlux™ model, an in silico analytical platform for modeling microbial consortia. The
110 computational modeling provides for the design of formulations with a balance of the
111 flow of metabolic inputs and outputs over time to target a specific metabolic output
112 and improved sustainability. The symbiotic formulation Sugar Shift consists of eight
113 strains of bacteria with GRAS (Generally Recognized as Safe) classification. The core
114 properties of this formula's design are the production of mannitol, with the concomitant
115 reduction of glucose and fructose, the production of anti-inflammatory components,
116 such as butyrate (20) and the antioxidant reduced glutathione (21).

117 This study was designed to determine whether Sugar Shift would be an effective
118 adjunct therapy to the prevailing standard of care to T2DM. This study was designed
119 as a double blind, placebo-controlled study aimed to evaluate the supplement Sugar
120 Shift in a population of Cuban T2DM patients during the course of 12 weeks. This
121 decision for the venue was made based on the excellence of the National Health
122 System in Cuba and the track record in well-conducted clinical trials (22) as well as on

123 the reports indicating that the epidemiology of T2DM in Cuba is similar to that of the
124 rest of the world (3).

125 Hypothesis

126 T2DM is a chronic metabolic disorder characterized by hyperglycemia, insulin
127 resistance and chronic inflammation (23). Several studies have reported gut
128 microbiome dysbiosis as a factor in rapid progression of insulin resistance in T2DM
129 that accounts for about 90% of all diabetes cases worldwide (1). Probiotics, prebiotics,
130 symbiotics, and postbiotics benefit metabolic diseases management, especially
131 obesity and type 2 diabetes mellitus (24). Sugar Shift is a symbiotic formulation
132 rationally designed for the conversion of glucose and fructose to support restoration of
133 the human gut microbiota, the modulation of intestinal glucose, and the production of
134 anti-inflammatory metabolites and therefore stabilize blood glucose, improve insulin
135 resistance, and reduce inflammation.

136

137 Materials and Methods

138 Study design

139 The study was designed and conducted as a randomized and double blind, placebo-
140 controlled trial to investigate the effect of Sugar Shift as a supplementary therapeutic
141 approach for T2DM with ISRCTN registry number ISRCTN48974890. The full trial
142 protocol is provided herein as supplementary material, including the English translation

143 of the approved document submitted to the Institutional Review Board for approval.
144 The CONSORT flowchart of the study is shown in Fig 1.

145 **Fig 1. CONSORT 2010 Flowchart of the Study**

146
147 The study was conducted at Hermanos Ameijeiras Clinical Hospital, an Academic
148 Medical Center in La Habana, Cuba. Fig 2 show outlines the study design and timeline.
149 No changes to the approved protocol by the Institutional Review Boards were made.

150
151 **Fig. 2. Schematic representation of the clinical study design.**

152 *The diagram represents the various elements and metrics used in the present study.*
153 *The Purple zone, representing the enrollment period, extended for more than 6 months,*
154 *until the number of participants exceeded the minimum required to achieve the power*
155 *of 0.8. The clinical study, represented by the blue bar, extended for exactly 12 weeks,*
156 *while the Analysis period (green bar) extended for more than 4 weeks. The boxes*
157 *contain the assays performed at the time periods indicated (in weeks) in the diagram*

158 **Ethical Considerations**

159 This trial was evaluated and approved under the Hermanos Ameijeiras Ethic Committee
160 for Clinical Investigation and The Hermanos Ameijeiras Scientific Council. The Sugar
161 Shift Probiotic supplements were also evaluated and approved for their use by the
162 Ethical Committee at the National Institute of Nutrition of Cuba and The Cuba Ministry
163 of Health. The study was conducted considering the Good Clinical Practice and in

164 accordance with the code of ethics of the World Medical Association Declaration of
165 Helsinki (25).

166 **Eligibility**

167 All patients diagnosed with T2DM (26) between 30 and 65 years old and body mass
168 index (BMI between 28-40) at baseline, who attended the diabetes specialized
169 consultations of the Hermanos Ameijeiras Hospital and who gave their consent to
170 participate in the study, without excluding sex or skin color, were selected. Patients
171 with chronic kidney disease, onco-proliferative diseases and pregnant women were
172 excluded.

173 **Power and sample size consideration**

174 The sample size was estimated with a two-sided alpha of 0.05, 95% confidence level,
175 standardized mean difference of 0.75, test power of 80%, expected proportion of
176 losses of 10%. Based on this information, the minimum required sample size was
177 estimated to be 28 individuals per group; adjusted for losses for various reasons, the
178 sample size was established at 32. The sample consisted of 64 patients who
179 consented to participate in the research.

180 **Patients Recruitment**

181 The recruitment period of the patients was from June 2021 to April 2022. The period
182 was extended due to Covid and lockdown. Patients were surveyed according to the
183 inclusion criteria and the discretion of the attending physician for inclusion in the study,
184 also we ask for information if the patients had had SARS-CoV-2 infection.

185 **Randomization**

186 The included patients were assigned to two treatment groups by randomization
187 technique: Group A (Sugar Shift) consisted of 32 patients who were assigned to the
188 treatment group, Group B (control): consisted of 32 patients who were given a placebo.
189 Assignment to treatment groups was randomized using the Epidemiological Analysis
190 from Tabulated Data (EpiData 3.1) software (<http://www.epidata.dk>). The list of random
191 numbers for each group was placed in the pharmacy. The assignment was made when
192 the patient's compliance with the inclusion and signature criteria for the informed
193 consent to participate in the study was verified. The products were dispensed by a
194 pharmacist who distributed a corresponding number of capsules to each patient,
195 according to the order of arrival at the pharmacy and this was noted in the medical
196 record. Both Sugar Shift and placebo were packaged in indistinguishable foil
197 packaging as well as same size capsules to maintain blinding. Subjects may be
198 unblinded if deemed medically necessary by their provider and the study principal
199 investigator (PI) in Cuba. However, in this study no subjects were unblinded.

200 **Delimitation and operationalization of variables**

201 The variables measured in this study were as follows: age (in years completed); sex
202 (female, male); nutritional evaluation (according to body mass index (BMI) = Weight in
203 Kg / Height in m²: low weight: < 18.5 Kg/m², normal weight: 18.5-24.9 Kg/m²,
204 overweight: 25-29.9 Kg/m², obesity: ≥ 30 Kg/m²).

205 The Primary response variable was hemoglobin A1c (HbA1c) (%). The Secondary
206 Response Variables were fasting glucose (FBG) (mmol/L), postprandial glucose (PPG) –

207 2h (mmol/L), insulin (mU/mL); total cholesterol (mmol/L), triglycerides (mmol/L), high
208 density lipoprotein (HDL-c) (mmol/L), low density lipoprotein (LDL-c) (mmol/L) and
209 lipopolysaccharide (LPS) levels determination mml/L).

210 **Trial intervention**

211 Subjects consumed Sugar Shift or placebo (Control Group) daily, two capsules per
212 day, 12 hours apart. The foil packaging containing the capsules were distributed every
213 28 days over the 12-week study period after blood sample collection for clinical
214 determination (Visit 1, Visit 28 and Visit 56 as timeline shown in Fig 1).

215 **Test substance**

216 The “test substance”, Sugar Shift was manufactured by BlisterPak Pro, LLC (Lafayette,
217 Colorado). Each capsule contains 96 mg (18 billion CFU) of a bacterial consortium of
218 eight strains of GRAS-classified bacteria that include *Bacillus subtilis* De111™,
219 *Bifidobacterium bifidum*, *Bifidobacterium longum*, *Lactobacillus paracasei*,
220 *Lactobacillus plantarum* TBC0036, *Lactobacillus reuteri*, *Leuconostoc mesenteroides*
221 TBC0037, and *Pediococcus acidilactici*. Each capsule contains 370 mg of prebiotics
222 and fillers consisting of inulin, microcrystalline cellulose, D-mannitol, and stearic acid.

223 **Placebo control**

224 The capsules, indistinguishable in appearance from the test substance, were similarly
225 manufactured by BlisterPak Pro, LLC (Lafayette, Colorado) and contained the same
226 ingredients in identical proportions as the test substance sans the microbial

227 consortium. Each placebo capsule contained 50 mg each of the prebiotics inulin and
228 D-mannitol and 270 of the fillers microcrystalline cellulose, and stearic acid.

229 **Organization and sample collection**

230 The patients, once randomized, were divided into subgroups for office visits to
231 facilitate instruction and clinical evaluation of the participants as well as sample
232 collection. Each group was cited every 28 days for sample collection and delivery of
233 supplements and clinical evaluation. Fecal samples from ten patients from each cohort
234 group were collected for microbiome characterization studies at Day 1 and Day 84 of
235 the study (for a total of 40 fecal samples).

236 All patients included in the study were measured for: FBG, PPG, cholesterol,
237 triglycerides, HDLc, LDLc, HbA1c, LPS, and fasting insulin. To obtain the biological
238 samples, the patients were instructed to fast for 8 hours. Whole blood samples were
239 obtained by venipuncture. The serum was obtained after centrifugation of the primary
240 sample within 1 hour to 1 hour 30 minutes after extraction, to be processed and
241 aliquoted for preservation and subsequent use. The preservation of aliquots of fasting
242 samples was carried out in the containers intended for this purpose at a temperature -
243 20 °C until used for LPS determination (Fig 1). The blood sample for the HbA1c
244 determination was dispensed in blood collection K3EDTA tubes (Hensco Medical
245 (Hangzhou) Co., Ltd.).

246 To ensure data security, electronic records of subject data were maintained using a
247 dedicated Microsoft Excel Database, Access to electronic databases was password
248 protected and limited to study staff and clinical staff supporting the subject's care. The

249 Hermanos Ameijeiras Hospital managed the security and viability of the information
250 technology infrastructure

251 **Adverse events (AE)**

252 This was a minimal risk study that involved the use of a commercially available dietary
253 supplement and AEs related to the study product beyond the potential for bloating or
254 excessive gas if taken in excess (beyond recommended dosing) were not anticipated.
255 Creatinine levels were measured to assess, the impact, if any, on the kidney of the
256 participants in all study groups.

257 **Clinical Determinations**

258 The determinations were made in a modular immunochemical autoanalyzer Cobas
259 6000, from Roche Diagnostic that meets the requirements stipulated in Directive
260 98/79/EC of the European Parliament and the Council of the European Union (EU) on *in*
261 *vitro* diagnostic medical devices, following the Standard Operating Procedures (SOPs)
262 in force, and with the quality standards required for them (Table 1).

263 **LPS determination**

264 The determinations of serum LPS levels (results expressed in Endotoxin Units) of
265 participating patients were made using the commercial kit ToxinSensor™ Endotoxin
266 Detection System (Version 11242021), following the manufacturer's instructions
267 (www.genscript.com).

268

269 Table 1 Quality Standards used with the Immunochemical Autoanalyzer Cobas 6000

Parameter	Range of Quality Control Standard
FBG	4.2 - 7 mmol/L
PPG	≤ 10 mmol/L
Cholesterol	3.6 – 5.2 mmol/L
Triglycerides	0.5 – 1.85 mmol/L
HDLc	≥ 0.9 mmol/L
LDLc	2.6 – 3.35 mmol/L
HbA1c	≤ 6%
Insulin	2.6 – 24.94 mIU/mL
Creatinine	47.6 – 113.4 μmol/L

270

271 **Microbiome Analysis**

272 Fecal samples were collected using DNA/RNA Shield™ Fecal Collection Tubes (Zymo
 273 Research, Irvine, CA) and stored at room temperature until processed.

274 *16S amplicon sequencing*

275 16S amplicon sequencing was performed by EzBiome (Gaithersburg, MD, USA).

276 Genomic DNA concentration was quantified using the Qubit fluorometer

277 (ThermoFisher, USA). The 16S rRNA V3-V4 regions within the ribosomal transcript were

278 amplified using the primer pair (Illumina-F: and Illumina-R, which contains the

279 gene-specific sequences and Illumina adapter overhang nucleotide sequences using

280 EzBiome’s established protocol. It is noteworthy to indicate that microbiome reference

281 standards (ZymoBIOMICS Microbial Community Standard, Zymo Research, Irvine, CA)

282 were used to quality control the process.

283 *Amplicon Taxonomic Assignment and Functional Prediction:*

284 Taxonomic profiling of 16S sequencing data was carried out by directly uploading
285 forward and reverse paired end reads to the EzBioCloud microbiome taxonomy
286 profiling platform (www.ezbiocloud.net) as described elsewhere (27). Briefly, the cloud
287 application of the EzBioCloud detects and filter out sequences of low quality regarding
288 read length (<80bp or >2,000bp) and averaged Q values less than 25. Denoising and
289 extraction of non-redundant reads are carried out using DUDE-Seq software (28). The
290 UCHIME (29) algorithm is applied against the EzBioCloud 16S chimera-free database
291 to check and remove chimera sequencing. Taxonomic assignment is performed using
292 the USEARCH program (30) to detect and calculate the sequence similarities of the
293 query single-end reads against the EzBioCloud 16S database. Sequencing reads are
294 clustered into OTUs at 97% sequence similarity using the UPARSE algorithm (31).
295 Reads from each sample were clustered into many OTUs using the UCLUST (32) tool
296 with the above-noted cutoff values. For the EzBioCloud 16S-based MTP pipeline, the
297 PICRUST2 algorithm (33) was used to estimate the functional profiles of the
298 microbiome identified using 16S rRNA sequencing. The raw sequencing reads were
299 computed using the EzBioCloud 16S microbiome pipeline with default parameters and
300 discriminating reads that were encountered in the reference database. The functional
301 abundance profiles of the microbiome are annotated based on bioinformatics analyses,
302 specifically by multiplying the vector of gene counts for each OTU by the abundance of
303 that OTU in each sample, using the KEGG (Kyoto Encyclopedia of Genes and
304 Genomes) (34) orthology and pathway database.

305 *Amplicon Comparative Statistical and Bioinformatic Analyses*

306 Subsampling, generation of taxonomy plots/tables and rarefaction curves, and
307 calculation of species richness, coverage, and alpha and beta diversity indices were
308 carried out in EzBioCloud Application. Briefly, microbial richness was measured by
309 ACE, Chao1, Jackknife and the number of OTUs found in the microbiome taxonomic
310 profile (MTP) index. The Shannon, Simpson and Phylogenetic α -diversity indices were
311 applied to estimate the diversity for each group using the Wilcoxon rank-sum test (35).
312 Beta diversity was calculated with Bray-Curtis (36), UniFrac and Generalized UniFrac
313 (37) distances based on the taxonomic abundance profiles. Permutational multivariate
314 analysis of variance (PERMANOVA) (38) were applied to measure the statistical
315 significances of β -diversity. Different groups were clustered with principal component
316 analysis (PCoA) based on abundance Jaccard distance metric. Kruskal-Wallis H test
317 (39) and LEfSe (40, 41) analysis were performed to determine enrichment in the
318 assigned taxonomic and functional profiles between groups. Taxonomic levels with
319 LEfSe values higher than 2 at a p-value < 0.05 were considered statistically significant.
320 The ggplot2 package in the R program (version 3.4.3., R Foundation for Statistical
321 Computing, Vienna, Austria) were used to visualize the LEfSe differences between the
322 groups. All the calculated p values were two-tailed and considered statistically
323 significant at $p < 0.05$.

324 **Statistical analysis**

325 *Clinical data*

326 The information collected was organized in an Excel database. These data were then
327 exported to the Statistical Package for Social Sciences (SPSS) version 23.0 system for
328 analysis and R For Windows - R: The R Project For Statistical Computing, version
329 4.2.0. Samples were characterized through the description of the variables of interest.
330 Qualitative variables were summarized in absolute numbers and percentages.

331 Quantitative variables were summarized in mean and standard deviation when data
332 presented a normal distribution, verified by the Kolmogorov-Smirnov test for normality
333 (42); if they did not present normal distribution, they were summarized in median and
334 interquartile range (IR).

335 To detect differences between the groups according to qualitative variables, the chi-
336 square test (χ^2) (43) was used. For the same purpose, the Student's t-test (44) was
337 applied in the case of age (quantitative variable).

338 The comparison of medians of the variables that provided information on the effect of
339 therapeutics between the different times (day 1, day 28, day 56 and day 84), was
340 performed using the Friedman test (45). In the case of the initial (day 1) and final (day
341 84) comparison, the Wilcoxon signed range test (46) was used.

342 The comparison of variance between both groups that provide information about of the
343 effect of probiotics therapeutics between the different times (day 1, day 28, day 56 and
344 day 84), was performed using the F-Test Two-Sample for Variances (47). Analysis of

345 covariance (ANCOVA) is a general lineal model which blends ANOVA and regression.
346 ANCOVA evaluates whether the means of a dependent variable (DV) are equal across
347 levels of a categorical independent variable (IV) often called a treatment, while
348 statistically controlling for the effect of other continuous variables that are not of
349 primary interest, known as covariates (CV) or nuisance variables. Mathematically,
350 ANCOVA decomposes the variance in the DV into variance explained by the
351 categorical IV, and residual variance. Intuitively, ANCOVA can be thought of as “
352 adjusting” the DV by the group means of the CV (s) The ANCOVA model assumes a
353 linear relationship between the response (DV) and covariate. (CV) (48). We worked with
354 the level of significance $\alpha = 0.05$ in all hypothesis tests.

355 To detect differences according to quantitative LPS and insulin determinations
356 between the groups and in the groups respect day 1 to day 84 the paired sample t-test
357 was applied as well as Pearson’s correlation (43). Also, the analysis assuming unequal
358 variance was made to detect the differences between day 1 and day 84 at a level of
359 significance $\alpha = 0.05$ to test the hypothesis.

360 *Microbiome data*

361 All statistical analyses were performed using packages ‘vegan’ v2.5-6, ‘phyloseq’,
362 ‘ggpubr’ and ‘ggplot2’ v3.3.2 in R 3.6.3 (<https://www.r-project.org/>). For microbiome
363 analysis, rarefaction depth was set at 25,000 reads. Shannon diversity index. (49),
364 Chao1 Index (50) and Good’s Coverage of library (51) were used to evaluate alpha
365 (within sample) diversity. Beta (between sample) diversity was examined using
366 multidimensional scaling analysis (MDA) (52) of Bray-Curtis (36) and Jaccard (53)

367 distances. The Wilcoxon rank-sum test (35) was used to compare alpha diversity
368 values between groups ($p > 0.05$). Statistical significance of beta-diversity distances
369 between stool processing workflows was assessed using PERMANOVA (38) with 999
370 permutations. Alpha diversity group significance was calculated using nonparametric
371 Kruskal-Wallis H test (39). Taxonomic features descriptive of each cohort were
372 identified using Linear Discriminate Analysis (LDA) Effect Size (LEfSe) (40), employing
373 the Kruskal-Wallis (KW) sum-rank test (39) to detect features with significant differential
374 abundance with respect to the class of interest. The biological significance is then
375 investigated using a set of pairwise tests among subclasses using the (unpaired)
376 Wilcoxon rank-sum test (35). As a last step, LEfSe uses Linear Discriminant Analysis
377 (54) to estimate the effect size of each differentially abundant feature and, if desired by
378 the investigator, to perform dimension reduction. Benjamini and Hochberg false
379 discovery rate correction factor (55) errors in null hypothesis testing when conducting
380 multiple comparisons.

381 **Results**

382 **Demographic and clinical characteristics**

383 Demographic and clinical characteristics at the beginning of the study were similar in
384 both randomized groups. A total of 60 individuals were included for this investigation,
385 30 per group, but 3 patients abandoned voluntarily the investigation after visit 1 for
386 personal or work-related circumstances. All of them were in the Control Group.
387 Ultimately, the study was comprised of 57 patients, 30 in the Study Group (Sugar Shift
388 Group) and 27 in the Control Group (Control Group).

389 Among the patients studied, there was a preponderance of the female sex for both
390 groups (Sugar Shift Group 60.0%, Control Group 51.9%). On average, the patients
391 were approximately 55 years old, minimum age 33 and maximum 65. No significant
392 differences were found in terms of sex ($p = 0.725$) or age ($p = 0.120$).

393 The distribution of patients according to nutritional assessment showed overweight
394 and obesity (Sugar Shift Group 53.3% and Control Group 51.9%). Patients were less
395 commonly of normal weight. No significant differences ($p = 0.722$) were detected in
396 both groups.

397 Regarding the type of treatment, diet plus oral hypoglycemic agents prevailed in both
398 cohorts (Sugar Shift Group: 63.3%, Control Group: 55.6%). No significant differences
399 were found regarding the type of treatment between the two groups ($p = 0.549$).

400 **Safety of the Symbiotic Product**

401 No adverse events were reported by participants in the Sugar Shift group. One
402 participant in the Control Group complained of bloating during the second visit (day
403 28).

404 Creatinine levels were measured and monitored to assess the impact, if any, Sugar
405 Shift has on kidney function (56). Normal levels of serum creatinine are 65.4 $\mu\text{mol/L}$ to
406 119.3 $\mu\text{mol/L}$ (57). Mean creatinine levels were not significantly different ($p = 0.24$)
407 between the Control Group at day 1 (77.17 $\mu\text{mol/L}$) and the Sugar Shift Group at day 1
408 (77.98 $\mu\text{mol/L}$). Similarly, there were no significant differences ($p = 0.21$) between the
409 control and the study group at the conclusion of the study with values of 77.17 $\mu\text{mol/L}$
410 in the control group and 77.97 $\mu\text{mol/L}$ in the group receiving Sugar Shift.

411 **Clinical Chemistry**

412 *Fasting Glucose (FBG)*

413 Fasting glucose levels showed that in three months this parameter is stabilized in the
414 Sugar Shift Group as compared with the Control Group See Fig 3.

415
416 **Fig 3. Variance trends in the Control Group and Sugar Shift Group cohorts during the 84-**
417 **day study period.**

418 *Variances for each sample set was calculated and plotted at four sample periods*
419 *indicated in Fig 2. Trend lines for each cohort are represented by dashed line. Solid*
420 *lines represent the plot of the actual variances. Red-colored lines represent results for*
421 *the Control group and Purple-colored lines represent the variances of the Sugar Shift*
422 *group. (a) Variance trends for fasting glucose. (b) Variance trends for 2-hour*
423 *postprandial glucose*

424
425 In the Sugar Shift Group, the median FBG was 7.5 mmol/L (135 mg/dL) at the
426 beginning of the study and remained at 7.2 mmol/L at the second (day 28) and third
427 doses (day 56) and resulted in an FBG value of 7.2 mmol/L (129.6 mg/dL) at the end of
428 treatment, with no significant differences between different times ($p = 0.942$). In the
429 Control Group, the behavior was different. There was a significant ($p = 0.001$) increase
430 in the median FBG value between the first and last day of treatment (7.5 mmol/L vs. 8.0
431 mmol/L) (Table 2).

432

Table 2. Levels of T2DM biomarkers during the course of the study.

Variables	Cohort	Study Days				P value
		Day 1	Day28	Day 56	Day 84	
		Descriptive statistics: Median (IR)*				
Fasting Glucose (mmol/L)	SS** Group	7.5† (4.5)	7.7 (5)	7.4 (5.1)	7.2 (4.1)	0.942 _a
	C** Group	7.5 (3.9)	7.3 (4.3)	7.8 (4.1)	8.0 (2.6)	0.001 _a
2h Post-Prandial (mmol/L)	Sugar Shift Group	11.1 (7.3)	11.5 (5.9)	10.1 (8.4)	10.9 (8.2)	0.646 _a
	C Group	9.5 (5.8)	10.1 (6.1)	9.3 (6.3)	10.8 (6.3)	0.013 _a
HbA1C (%)	SS Group	7.2 (1.9)	ND	ND	7.2 (1.9)	0.262 _b
	C Group	6.8 (2.1)	ND	ND	7.2 (3.4)	0.387 _b
HOMA IR index	SS Group	8.65 (5.5)	ND	ND	7.12 (3.9)	0.002
	C Group	11.54 (14.2)	ND	ND	12.51 (8.2)	0.191

434

435 * IR = Interquartile Range

436 **SS = Sugar Shift treated cohort; *C = Placebo control cohort

437 a= Friedman Test

438 † Multiply the value in mmol/L by 18 to obtain values in mg/dL

439

440 In consideration of the differences observed at the end of treatment between both
441 groups (day 56 and Day 84), we performed the analysis of variance between both
442 groups. The variability of FBG in Control Group is much greater (23.88) than in Sugar
443 Shift Group (8.26) after 12 weeks of treatment (84 days) (Table 3, Fig 3a). The Analysis
444 of Covariance (ANCOVA) (48) was in concordance between both groups at 84 days.
445 The ANCOVA results show a negative covariance between groups ($z=-6.85$, $p(z)=$
446 $7.62257E-12$), indicating that fasting glucose increases in the Control group and
447 decreases in Sugar Shift Group at the end of 12 weeks (Table 3).

448 Table 3: Comparison of variances between groups in fasting glucose levels

Variable		Study Days			
		Day 1	Day28	Day 56	Day 84
		Descriptive statistics: Variance (Mean)			
Fasting Glucose (mmol/L)	Sugar Shift Group	7.30(8.29)	7.31 (8.29)	11.49 (8.48)	8.99(8.31)
	C. Group	8.59(8.43)	8.59(8.43)	19.34(8.34)	23.9 (9.4)
P(F<=f) one-tail		0.33	0.33	0.089	0.006
P(Z<=z) one-tail		0			3.81128E-12
P(Z<=z) two-tail		0			7.62257E-12
F Critical one-tail		1.891466319			
z Critical one-tail		1.644853627			
z Critical two-tail		1.959963985			

449


450 *Postprandial glucose – 2h*

451 Regarding postprandial glucose, the median values in Sugar Shift Group were 11.1 and
 452 11.5 mmol/L in the early stages of the study and in the last two measurements, showed
 453 a slight decrease (10.1 and 10.9 mmol/L) that was not significant (p = 0.646). In the
 454 Control Group, however, a slight increase at the end of the treatment was significant with
 455 respect to the stable values of the Sugar Shift group (p = 0.013) (Table 2). The declining
 456 trend in pp glucose from day 1 to day 84 was similar to FBG (Fig 3b) even when no
 457 significant differences was observed at the end of the study in analysis of variance
 458 between both groups (p = 0.62). The ANCOVA results show a negative covariance
 459 between the Control group (26.817) and the Sugar Shift group
 460 (-0.0289), indicating that postprandial glucose increases in the Control group and
 461 decreases in Sugar Shift Group at the end of 12 weeks. The kinetics of cohort variances
 462 throughout the study for both FBG and PPG can be observed in Fig 3.

463 *Glycosylated Hemoglobin (HbA1C)*

464 The analysis of HbA1C showed that no significant change occurred in either the Sugar
465 Shift Group or the Control Group. Glycosylated hemoglobin was found, on average, at
466 7.2% in the two measurements made (day 1 and day 84) in the study group. In patients
467 in the Control Group, at baseline, it was 7.3% and, at the end, 7.4%. No significant
468 differences were found (Table 2). It is noteworthy that a 90-day trial period may not
469 have been sufficient for either group to be a clear indicator of improvement in view that
470 the RBC cycle is approximately 120 days (58).

471 *Cholesterol*

472 The data collected during this aspect of the study, as well as the metadata of the
473 participating patients, are listed in Table S1  TABLE S1.xlsx . Mean cholesterol levels were not
474 significantly different ($p = 0.371$) in the Sugar Shift Group while there was a significant
475 ($p = 0.0007$) increase in mean cholesterol values in the Control Group. The F-test Two-
476 Sample for Variance analysis revealed a significant increase ($p = 0.00032$) in variance
477 from day 1 to day 84 for the Control Group but not significant ($p = 0.391$) for the Sugar
478 Shift Group. Mean cholesterol values for the Control Group were 4.41 mmol/L at day 1
479 and 5.14 mmol/L at day 84. For the Sugar Shift Group, mean cholesterol values
480 remained steady at 4.31 mmol/L at day 1 and 4.42 mmol/L at day 84. Variances for this
481 latter group were 0.645 and 0.584, respectively. For the Control Group at days 1 and
482 84, the variances were 0.311 and 1.644, respectively.

483 *HDL and LDL Cholesterol*

484 The means of the HDLc values of day 1 and day 84 for the Sugar Shift group were 1.19
485 and 1.39, respectably. Similarly, the mean values for the Control group were 1.17 and
486 1.12 for Days 1 and 84, respectively. These values were not statistically significant
487 when the two groups were compared. The variances, however, between Day 1 and 84
488 of the SS group were 0.12 and 2.72, respectively. These were statistically significant (p
489 = 0.00012). The Control group, however showed no significant ($p = 0.137$) variances
490 between Day 1 (variance = 0.07) and Day 84 (variance = 0.11).

491 *Triglycerides*

492 Triglyceride levels were reduced, on average, from 2.1 to 1.7 mmol/L in the Sugar Shift
493 Group and from 2.4 to 1.6 mmol/L in the Control Group, results that were significant in
494 both cases (Sugar Shift Group: $p = 0.005$; Control Group: $p = 0.002$). The analysis of
495 variance between groups no showed significant differences.

496 *Insulin*

497 Insulin levels were measured for all study participants and then analyzed statistically
498 using both the t-Test (paired) and F test for analysis of variance. The Control Group
499 (Days 1 and 84) and Sugar Shift Group (Day 1) participants showed higher insulin
500 concentrations than those in the Sugar Shift Group after 84 days of treatment (Table 4).
501 Using the t-Test Paired Two-Sample for Means the p values for Sugar Shift Group Day
502 1 and Sugar Shift Group Day 84 was $p = 0.02$ and interpreted as significant.
503 Conversely, the Control group (Day 1 and Day 84), and Control Day 1 and Sugar Shift

504 Group Day 1 were 0.12 and 0.11, respectively. However, the p value. For this latter
505 pair, the Mean for Day 1 participants was 9.01 with a Variance of 92.24 as compared to
506 the Sugar Shift Group Day 84 group, which showed a Mean of 7.09 and a Variance of
507 29.05. By way of comparison, the Mean values for Control Group Day 1 and Control
508 Group Day 84 were 11.27 and 12.34, respectively with corresponding Variances of
509 131.44 and 170.74.

510 The F-test showed similar results. Day 1 of both groups were not significantly different
511 ($p = 0.192$) while for Day 84, the Control and Sugar Shift participants were significantly
512 different ($p = 2.41 \times 10^{-6}$) with means of 12.5 $\mu\text{U/L}$ for the Control Group and 8.64 $\mu\text{U/L}$
513 for the Sugar-Shift treated group, representing a 30.9% reduction in insulin levels in
514 those patients receiving the symbiotic formulation.

515 Table 4. Statistical analysis using the t-Test for Paired Samples for Means for serum insulin in the treated and control
 516 groups

Metric	t-Test: Paired Two Sample for Means - Insulin (mIU/L)							
	<i>SS_D1*</i>	<i>SS_D84</i>	<i>C_D1*</i>	<i>C_D84</i>	<i>CD_D1*</i>	<i>SS_D1</i>	<i>C_D1*</i>	<i>SS_D84</i>
Mean	9.00694744	7.08535518	11.2669246	12.334936	11.2669246	7.86968928	12.334936	6.2201627
Variance	92.241692	29.057633	131.74252	172.73747	131.742529	37.454623	172.737474	15.9212268
Observations	31		27		27		27	
Pearson Correlation (59)	0.913198142		0.936299149		-0.126860439		-0.047453887	
df	30		26		26		26	
t Stat	2.068872866		-1.183398856		1.290814199		2.283333364	
P(T<=t) one-tail	0.023634798		0.123679404		0.104064286		0.015413179	
t Critical one-tail	1.697260887		1.70561792		1.70561792		1.70561792	
P(T<=t) two-tail	0.047269596		0.247358807		0.208128571		0.030826357	
t Critical two-tail	2.042272456		2.055529439		2.055529439		2.055529439	

517 *SS = Sugar Shift Cohort, C = Control Cohort, D1 = Day 1 of the study; D84 = Day 84 of the Study.

518 *Insulin Resistance*

519 HOMA-IR, as an indicator of insulin resistance, was calculated according to the
520 formula: fasting insulin ($\mu\text{U/L}$) x fasting glucose (nmol/L)/22.5. The Control Group
521 (Days 1 and 84) and Sugar Shift Group (Day 1) participants showed higher HOMA-IR
522 values than those in the Sugar Shift Group after 84 days of treatment (Fig 4).
523 Boxplots were generated using the script “*ggboxplot*” in the library “*ggpubr*”
524 (<https://cran.r-project.org/web/packages/ggpubr/index.html>) with “jitter” to show
525 data distribution.

526
527 **Fig 4. Boxplots showing distribution data gathered from HOMA-IR calculations of**
528 **before and after treatment for both the Control Group- and Sugar Shift Group-**
529 **treated cohorts.**

530 *Boxplots were plotted with ggboxplot using pairwise comparisons among the four*
531 *possible groups. The “jitter” function was added to show the distribution of*
532 *datapoints for each of the pairwise comparisons and to assess the relationship*
533 *between the measurement variable and the categorical variable. The significance (p*
534 *= 0.05) in Chao1 indices between each group pair is illustrated as the probability*
535 *value as calculated using the Wilcoxon signed-rank test (values on top of each*
536 *graph)*

537

538 Using the F-Test Two-Sample for Variance, the p values between the Control Group
539 (Day 1 and Day 84) and Control Group Day 1 and Sugar Shift Group Day 1 were 0.24
540 and 0.18, respectively. However, the p value for Sugar Shift Group Day 1 and Sugar
541 Shift Group Day 84 was $p = 0.0071$ and interpreted as significant. For this latter pair,
542 the Mean HOMA-IR index was 11.27 with a Variance of 94.19 as compared to the
543 Sugar Shift Group Day 84 group, which showed a Mean of 8.84 and a Variance of
544 28.13. By way of comparison, the Mean values for Control Group Day 1 and Control
545 Day 84 were 11.27 and 12.33, respectively with corresponding Variances of 131.74
546 and 172.74.

547 *Serum Lipopolysaccharides (LPS)*

548 Serum LPS was measured for all participants in the two cohort groups. The results
549 are summarized in Fig 5 and Table 5. There was a significant difference between day
550 1 and day 84 in the Sugar Shift Group (0.00099). Similarly, significant differences
551 were observed in the levels of serum LPS between the Control and Treated groups
552 after 84 days of treatment ($p = 0.012$). No significant difference was noted in the
553 Control Group ($p = 0.0.922$).

554 **Fig 5. Violin plots showing the distribution of LPS values for each study group.**

556 *Violin plots were chosen to show the distribution of LPS values of samples within*
557 *each study group. Wider sections of the violin plot represent a higher probability that*
558 *members of the population will take on the given value; the skinnier sections*

559 represent a lower probability. The colored dots within the bar plot represent the
 560 mean values for the study group while the black line indicates the median.

561 Table 5. Paired samples t- Test for means among cohorts and sample times for serum
 562 LPS

Pair	Mean Diff	Variance Diff	Pearson Correlation	t statistic	p value	Significance*
CD01- CD84	0.038875	0.007078	0.91995	1.77522	0.92199	NS
SSD01- SSD84	0.150666	0.816646	0.29366	4.02503	0.00099	S
SSD01- CD01	-0.00537	-0.01091	-0.18955	-0.0727	0.47202	NS
SSD84- CD84	-0.12833	-0.02032	-0.35052	-2.5965	0.012	S

563 *NS = not significant; S = significant

564 Microbiome analysis

565 A total of 40 samples, 10 samples from each cohort were collected before and after
 566 treatment and processed as described above. The mean sequence length per
 567 sample was $21,333 \pm 7,288$ base pairs (bp) with a mean Q value of 37.2 as
 568 determined using FastQC (60).

569 *Alpha Diversity*

570 Species richness, as determined using the Chao1 Index (50), showed a significant
 571 increase (Wilcoxon's signed-rank test) (61) between Day 1 of treatment with Sugar
 572 Shift and day 84 ($p = 0.0089$). Similarly, there was a significant difference between
 573 the Control and the Treatment group at the end of the 12-week study ($p = 0.011$). No
 574 such significant differences were noted between the two groups at the beginning of

575 the study ($p = 0.80$) or the Control Group at the beginning and end of the study ($p =$
576 0.80). No significant difference in the Shannon Diversity Index as measured by the
577 Wilcoxon's rank test was observed among the various groups. Good's Coverage (51)
578 of data showed no significant difference in coverage among the two groups, before
579 and after treatment. The mean coverage was 99.83 ± 0.54 . Alpha Diversity (Chao1)
580 boxplots with "jitter" are shown in Fig 6.

581
582 **Fig 6. The Chao1 alpha diversity of Control Group- and Sugar Shift Group-treated**
583 **patients is represented in boxplots with jitter showing inter- and intra-group data**
584 **distribution.**

585 *The number of species in each of the pairwise comparisons of fecal microbiomes*
586 *are illustrated in these graphs as the Chao1 Index. Each dot represents a data point*
587 *for each sample. The significance ($p = 0.05$) in Chao1 indices between each group*
588 *pair is illustrated as the probability value as calculated using the Wilcoxon signed-*
589 *rank test (values on top of each graph).*

590

591 *Beta Diversity*

592 No significant changes were noted in Beta Diversity among the groups evaluated.
593 UPGMA clustering(62) revealed that microbiome samples from individuals clustered
594 together, regardless of the date of sample collection. While the results show a
595 difference in Unifrac distances (37) between Day 1 and Day 84 in the Sugar Shift
596 cohort, this difference was not statistically significant ($p = 0.989$).

597 *Taxonomic Biomarkers*

598 Taxonomic biomarkers were determined using both Kruskal-Wallis H test (39) and
599 LefSe analysis (40). Two taxonomic biomarkers were identified. When comparing
600 Day 1 and Day 84 of the Sugar Shift treated cohort, several taxonomic biomarkers
601 were identified, both, via the Kruskal-Wallis H test and LEfSe analysis. Significant
602 increases in abundance of several genera of the *Lachnospiraceae* family ($p = 0.008$),
603 specifically *Blautia* ($p = 0.02008$), *Dorea* ($p = 0.02448$), *Coprococcus* ($p = 0.0322$)
604 and *Kineothrix* ($p = 0.2378$) as well as *Prevotella* ($p = 0.013$) and *Bifidobacterium* ($p =$
605 0.011) and *Faecalibacterium prausnitzii* ($p = 0.0018$). Significant decreases in relative
606 abundance of *Enterococcus* ($p = 0.04696$), *Vagococcus* ($p = 0.00335$),
607 *Ruminococcus* ($p = 0.04116$) and *Peptostreptococcaceae* ($p = 0.04508$).
608 *Clostridium innocuum* group, showing a decrease from 0.05211 on Day 1 of the
609 study to 0.00183 at Day 84 with an LDA effect size of 3.10536 and a p-value of
610 0.03051. Conversely an increase in *Agathobaculum* sp. was noted from day 1
611 (0.16824) to Day 84 (0.44657) with an LDA effect size of 2.34567 and a p-value of
612 0.4254.

613 *Functional Biomarkers*

614 Profiling phylogenetic marker genes, such as the 16S rRNA gene, is a key tool for
615 studies of microbial communities but does not provide direct evidence of a
616 community's functional capabilities. PICRUSt was developed for predictive
617 functional capabilities using 16S rRNA. Functional prediction using PICRUSt (63, 64)
618 and LEfSe (41) revealed significant differences between the Day 1 and Day 84 of

619 treatment with Sugar Shift in the gut microbiome in the relative abundance of
 620 microbial genes related to certain metabolic pathways associated with carbohydrate
 621 and lipid metabolism (Table 6).

622 **Table 6. Principal Functional Biomarkers identified by PiCRUST and LEfSe Analysis**
 623 **of Treated in the Sugar Shift cohort.**

Ortholog	Definition	p-value	Relative Abundance of Genes		
			SugarShift Day 1	SugarShift Day 84	% Diff
K09884	Aquaporin related protein, invertebrate	0.006302132	9.24575E-05	3.4468E-06	-96%
K13319	4-ketoreductase	0.016411893	8.132E-07	5.5744E-06	585%
K16913	proline-, glutamic acid- and leucine-rich protein 1	0.028365506	8.39499E-05	0.0001535 ₃	83%
K07224	iron uptake system component EfeO	0.028365506	0.001658944	0.0028216 ₄	70%
K15578	nitrate/nitrite transport system ATP-binding protein	0.034293721	0.015285072	0.0115972 ₉	-24%
K21113	cytochrome P450 family 106	0.035999193	3.214E-07	3.2456E-06	910%
K22317	acyl-CoA:acyl-CoA alkyltransferase	0.035999193	6.427E-07	4.9079E-06	664%
K22336	bacterioferritin B	0.035999193	6.427E-07	4.6237E-06	619%
K00691	maltose phosphorylase	0.049366195	0.002707086	0.0007913 ₅	-71%

624

625 Discussion

626 In this study, we have shown that in a short period of administration (twice daily for
 627 12 weeks) of the symbiotic formulation Sugar Shift to T2DM patients, there were
 628 significant differences between the treated and control group on several key metrics:

629 fasting blood glucose, insulin, HOMA-IR and serum LPS. This study also provides
630 evidence that supports the benefits of the administration of this formulation as an
631 adjunct therapy for the control of insulin resistance and in the lipidic profile in
632 diabetic. The HbA1C and postprandial glucose, however, did not show significant
633 differences as compared to placebo.

634 Meta-analysis studies have been summarized for a great diversity of published
635 studies in which different probiotic formulations have been evaluated for patients
636 suffering from T2DM (65, 66). Many of these studies have shown significant
637 variations in the values of HbA1c and fasting glucose. (67-69). Others, however, have
638 not shown such movements. (70, 71).

639 Measuring HbA1c is an accepted and valued method to estimate long-term average
640 glycemia (72). These levels are associated with erythrocyte (RBC) longevity in
641 peripheral circulation. Erythrocyte survival curves turnover may explain the
642 discrepancy in the reported results (67-69, 71). The strong correlation of glycation
643 rate with whole blood HbA1c in the DM and NDM subjects provides evidence that
644 the whole blood determination depends on the integration of glycation rate
645 throughout the red cell life span (73). In addition to RBC life span, there may be other
646 variables that either attenuate or amplify the discordances between Hb A1c and
647 average plasma glucose. In healthy adults, complete turnover average 120 days,
648 during which time approximately 1.7×10^{11} cells are renewed each day (74). The
649 analysis conducted on RBC survival curves from Cohen et al. (73) suggests an
650 average erythrocyte circulation time of 80 ± 11 days. In view of this observation, it

651 can be assumed that a large proportion of the glycosylated erythrocytes present in
652 peripheral circulation of both the study cohorts at the beginning of the study were
653 still present after 84 days. These observations may explain the similarity in the levels
654 of HbA1c at both sampling times. A 3-month study is not sufficiently long to clearly
655 assess the effect of the test substance (Sugar Shift) on HbA1c levels. Therefore, it is
656 recommended that future studies may be extended for an additional 3 months to
657 assess the impact of Sugar Shift, if any, on HbA1c levels.

658 **Clinical Chemistry**

659 To analyze the effects of Sugar Shift on glycemic control evaluated by FBG,
660 postprandial glucose and HbA1c levels, it is important to analyze the characteristics
661 of the patients who participated in the study. As can be seen from the median
662 values, both groups consisted of individuals with stable values of their glucose and
663 HbA1c parameters due to previously implemented diabetic treatments. This reflects
664 the action of the hypoglycemic treatments that most of both cohorts were taking
665 prior to the beginning of the study as well as the intervention of the endocrinologists
666 in their follow-up during the time of the COVID 19 pandemic, which preceded the
667 study (75-77).

668 ***Serum glucose and HbA1c***

669 At the latter part of the study period (days 56 and 84) it was observed that the FBG
670 values of the individuals in the control group increased significantly (Fig 2). Glucose
671 levels in the Sugar Shift Group, on the other hand, remain constant, with a tendency
672 to decrease towards the final day of the study (day 84). These data differ significantly

673 between study groups. F-test data showed a $p = 0.006$ when comparing the
674 variance between the Control and the Sugar Shift Group at the end of the study.
675 Covariance studies (78) showed a negative covariance (-0.6086977), that is, they are
676 moving in opposite directions (78). These results indicate that while levels of FBG are
677 increasing in the Control Group, they are decreasing in the Sugar Shift Group, and for
678 the 84-day study, these values remained stable in the Sugar Shift cohort.

679 The meta-analysis by Hu Y-m, et al. (66) on the effects of different probiotic
680 supplements in patients with T2DM showed that, in many studies the probiotic
681 supplements evaluated, regardless of the study design, the duration of treatment (6-
682 12 weeks) and the doses of the supplements produce a slight reduction in FBG and
683 an inappreciable change in HbA1c. These results are in concordance with the results
684 presented here.

685 Among the possible mechanisms of probiotic therapy is promotion of a
686 nonimmunologic gut defense barrier, normalization of increased intestinal
687 permeability and improved gut microecology play key roles. Another possible
688 mechanism of probiotic therapy is improvement of the intestine's immunologic
689 barrier, particularly through intestinal immunoglobulin A responses and alleviation of
690 intestinal inflammatory responses, which produce a gut-stabilizing effect (79, 80).

691 Our results also suggest that if stabilization occurs after day 56, this trend should be
692 evaluated over a period longer than 3 months. Studies evaluating the action of
693 probiotics in longer periods of time find significant decrease in HBA1c and FBG
694 values (65, 81, 82).

695 Another important aspect in the optimal T2DM management is the PP Glucose
696 control. This parameter is often difficult to achieve because different mechanisms
697 are involved. The macronutrients composition and also the sequence and timing of a
698 meal gastric emptying/intestinal glucose absorption, gastrointestinal hormones,
699 hyperglycemia mass action effects, insulin/glucagon secretion/action, de novo
700 lipogenesis and glucose disposal are integrated via the central nervous system for
701 optimal regulation and potentially, to reduce postprandial glucose fluctuations and
702 thereby, HbA1c (83, 84). The contribution of the microbiome to this control,
703 particularly in post prandial glucose is not well recognize yet, but our results showed
704 a coincident tendency in the behavior of FBG and Post Prandial Glucose, so we
705 believe that the symbiotic intervention in a period more than 12 weeks is a promising
706 approach to regulate via gut healthy bacterial the hyperglycemia after meals in
707 T2DM patients (85).

708 Considering the above, as well as the results obtained, we can hypothesize that
709 Sugar Shift promotes a stabilization of the gut microbiome as a precursor to a
710 noticeable decrease in FBG. This process could be due to the impact of Sugar Shift
711 on the relative abundance and composition of the gut microbiota during the course
712 of treatment. Sugar Shift was designed to endogenously convert glucose and
713 fructose to mannitol in the GI tract The principal producers of mannitol in the
714 consortium are *Leuconostoc mesenteroides* and *Lactobacillus reuteri* (results not
715 shown here), and the principal glucose consumer are *B. longum* and *B. bifidum* (82).
716 In addition, the symbiotic formulation controls the inflammation by butyrate

717 production as indicated by an increase in the number of genes and species
718 associated with butyrate production in the study group at Day 84. *Pediococcus*
719 *acidilactici*, *Lactobacillus paracasei*, *Bifidobacterium longum* and *Lactobacillus*
720 *reuteri* are the principal butyrate producers in the Sugar Shift consortium. The net
721 production of butyrate was predicted by the BioFlux™ model to be 4.5×10^5 mmol/h
722 (86). Thus, the Sugar Shift therapy may help stabilize the gut microbial environment
723 in 12 weeks of treatment and thereby prevent the generation of inflammatory
724 mediators such as LPS and T2DM dysregulation (16, 80, 87).

725 *Lipids*

726 The analysis of the lipid profile shows a stabilization in the normal values of
727 cholesterol in the Sugar Shift Group and a significant increase of these values in
728 Control Group. Longer term studies are needed to assess the full impact on blood
729 cholesterol. The colonization of the intestine by *Bifidobacterium* and *Lactobacillus*
730 probiotics may affect the regulatory mechanism of conversion of cholesterol into bile
731 acids and its elimination in the feces (88). These probiotic bacteria likely incorporate
732 the cholesterol into their plasma membrane, convert it into coprostanol and
733 deconjugated bile acids by the activity of the enzyme bile salt hydrolase (BSH) (89,
734 90). The activity of the BSH increases with the long-term colonization of the gut by
735 *Bifidobacterium*- and *Lactobacillus*-containing probiotics, promoting a higher degree
736 of BSH activity, thus, increasing the production of deconjugated bile acid (88). The
737 decrease in cholesterol by this metabolic pathway would explain the slight increase

738 in HDLc in the Sugar Shift Group, since the elimination of excess cholesterol would
739 not be through the main pathway.

740 The decrease in triglyceride levels was significant in both groups. In the treated
741 group it could be due in part to the regulation exerted by probiotic bacteria (91)
742 linked to the diet (92) and increased physical activity of individuals in both study
743 groups (93). The analysis of physical activity, as measured by questionnaire, showed
744 that physical activity was higher in the Control Group compared to Sugar Shift
745 Group (66.6% vs 50%, respectively). This suggest that the effect of the probiotics
746 regulatory mechanism could be increase by the incorporation of physical exercise.

747 Animal studies indicate that the composition of gut microbiota may be involved in
748 the progression of insulin resistance to type 2 diabetes (94). Several meta-analysis
749 studies on the use of probiotics in T2DM show that most of these nutritional
750 supplements decrease insulin in a short period of time significantly, even if other
751 parameters such as HbA1c are not modified (65, 66, 91, 95). This is consistent with
752 what was found in our study.

753 *Insulin*

754 Insulin resistance is a pathological state in which tissues do not respond normally to
755 insulin in the process of glucose metabolism (96). Various factors have been
756 implicated in the pathogenesis of insulin resistance (23, 97-99), including genetic
757 predisposition, aging, obesity, and a sedentary lifestyle. More recently, the gut
758 microbiota has been considered to be a key factor leading to the insulin resistance
759 (100). The exact microbial mediators and mechanisms that link features of different

760 gut microbial communities to changes in insulin secretion are not yet known (101). It
761 is possible that microbes or their components such as muropeptides and LPS,
762 penetrate the gut barrier and interact with receptors within the pancreas or insulin-
763 responsive tissues and compromise endocrine control of metabolism and promote
764 hepatic and peripheral insulin resistance, thereby worsening blood glucose. The
765 LPSs interaction with Toll-like receptor 4 promotes inflammation in metabolic tissue
766 and this innate immune response could be involve in the poor control of blood
767 glucose. So, probiotics may be a promising approach to improve insulin sensitivity
768 by favorably modifying the composition of the gut microbial community by the
769 modification of the gut bacterial and reducing intestinal endotoxin concentrations,
770 thus reducing inflammatory signaling and decreasing the insulin resistance (101).

771 **Microbiome Analysis**

772 Species richness showed a significant increase (Wilcoxon's rank-sum test) between
773 Day 1 of treatment with Sugar Shift and day 84 ($p = 0.0089$). This suggests that the
774 microbial consortium promotes an increased diversity in the gut microbiome. higher
775 microbiome α diversity, along with more butyrate-producing gut bacteria, was
776 associated with less T2DM and with lower insulin resistance among individuals
777 without diabetes (102, 103).

778 Our study indicates that the use of symbiotic formulation Sugar Shift induces a
779 significant modification of LPS concentration that is in concordance with the
780 modification of insulin resistance, lipids modification and FBG reduction. The
781 microbiome analysis confirms this hypothesis. The gut microbiome dysbiosis of

782 patients with T2DM correlates well with increased LPS levels and its impact on the
783 presence of inflammatory biomarkers in serum, which may provide insight into
784 potential diagnostic and therapeutic approaches in the treatment of T2DM (104).

785 *Taxonomic biomarkers*

786 Gut microbiota-derived LPS is an important factor involved in the onset and
787 progression of inflammation and metabolic diseases, including T2DM (105). The
788 composition of the gut microbiota is altered in T2DM with a concomitant reduction
789 of SCFA producers, notably butyrate (106). LPS, bacterial surface glycolipids,
790 produced by Gram-negative bacteria are known to induce acute inflammatory
791 reactions (107), particularly in the context of sepsis. However, LPS can also trigger
792 chronic inflammation (104). In the case of T2DM and other metabolic diseases
793 originating from chronic inflammation of the gut, the source of LPS is not an external
794 infection, but rather an increase in endogenous production, which is usually
795 sustained by the gut microbiota (107).

796 The microbiome analysis showed a significant increase ($p > 0.01$) in abundance of
797 several genera of the Lachnospiraceae family in treated group as compared to
798 control group. The compiled data from the Human Microbiome Project (108, 109)
799 and Meta Hit (110) revealed that the human microbiota comprises 12 different phyla,
800 of which 93.5% belong to Firmicutes, Bacteroidetes, Proteobacteria, and
801 Actinobacteria. Among these, Firmicutes and Bacteroidetes dominate the gut
802 microbiota in healthy subjects. The Lachnospiraceae family is a phylogenetically and
803 morphologically heterogeneous taxon belonging to the clostridial cluster XIVa of the

804 phylum Firmicutes (37). Lachnospiraceae belong to the core of gut microbiota,
805 colonizing the intestinal lumen from birth and increasing, in terms of species
806 richness and their relative abundances during the host's life. However although,
807 members of Lachnospiraceae are among the main producers of SCFA, different taxa
808 of Lachnospiraceae are also associated with different intra- and extraintestinal
809 diseases, that is why this genera of bacteria have a controversial role in health and
810 disease (111). This association depends on the predominant species of this genera
811 in the microbiome (111, 112).

812 In a normal human physiologic state, 90–95% of the SCFAs present in the colon and
813 in the general systemic circulation are constituted by acetate, propionate and
814 butyrate, with intraluminal concentrations of approximately 60% C2, 25% C3 and
815 15% C4 (113). Butyrate is a SCFA reported to be the major source of nutrition for
816 colonic epithelial cells (114) with anti-inflammatory effects by induction of regulatory
817 T cells, downregulation of pro-inflammatory cytokines and the Toll-like receptor
818 (TLR) 4 receptors, thus reinforcing insulin sensitivity and glucose metabolism.(115).
819 On the other hand, butyrate induces the Activation of G protein-coupled receptor
820 (GPR) 43. This binding suppresses colonic inflammation, therefore protecting the
821 liver and down- regulating insulin signal transduction in adipose tissue. Butyrate is
822 also involved in modulating appetite and lipolysis inhibition, which in turn, decrease
823 circulating lipid plasma levels and body weight (113). Recent studies on the
824 composition and functionality of the microbiome in obese children demonstrated
825 that insulin resistance was associated with decreased microbial α -diversity

826 measures and abundance of genes related to the corresponding metabolic
827 pathways (116).

828 In our results we found a significant increase of α diversity at Day 84 in the group of
829 treatment with Sugar Shift. These data support our hypothesis because of the
830 significant decrease in LPS concentration and in HOMA-IR Index in the treated
831 group with Sugar Shift are related to de increase of α diversity in the microbiome of
832 this people.

833 There was a significant ($p = 0.025$) increase in the relative abundance of
834 *Bifidobacterium* spp. between both pre-treatment groups (0.63 ± 1.14) and the
835 Sugar Shift Group after 12 weeks of treatment (2.75 ± 3.84). Increased relative
836 abundances of this genus is notably reported in association with successful
837 treatment with probiotics and in non-diabetic, “healthy” individuals (117, 118). It is
838 also plausible to hypothesize that the Bifidobacteria present in Sugar Shift colonize
839 the intestines and help restore the homeostasis of the gut microbiota and increase
840 the relative abundance of SCFA producers, thus, alleviating inflammation. This
841 interaction, however, would need to be supported by whole genome and
842 metabolomic studies.

843 It is noteworthy that *Faecalibacterium prausnitzii* is a highly represented (44%
844 increase from the same patients at the beginning of the study) in the gut microbe of
845 Sugar Shift-treated patients. This taxon is generally abundant in the microbiome of
846 “healthy” individuals, but it is present at reduced levels in individuals with
847 gastrointestinal inflammatory diseases (e.g., diabetes). It has therefore been

848 suggested to constitute a marker of a healthy gut and is associated with anti-
849 inflammatory properties (119, 120). Among its attributes, *F. prausnitzii*, is an acetate
850 consumer that produces butyrate and bioactive anti-inflammatory molecules such as
851 shikimic and salicylic acids (121). This protective system SCFAs that are significant
852 end-products that re involved in the fermentation process of the bacteria that exist in
853 the human colon and ameliorates the effects of LPS (122). The significant decrease
854 in serum LPS noted among the Sugar Shift-treated study group (Fig 3) may be
855 attributed, at least in part, to the role of *F. prausnitzii* in the production of SSFAs and
856 other anti-inflammatory substances.

857 *Functional biomarkers*

858 Putative, functional biomarkers were identified using PICRUST2 to infer functional
859 gene relative abundances from taxonomic data and LEfSe to determine
860 discriminatory features that explain functional and taxonomic between the study
861 groups. While these tools serve to identify differences based on gene relative
862 abundance, rather than by function, it is noteworthy that several of the
863 discriminatory orthologs identified play a role in T2DM. Many of which are related to
864 iron metabolism, in particular orthologs K07224, K22317, and K22336.
865 The blood sugar levels are closely related to the iron contents in islet b-cells.
866 However, because of the higher expression levels of iron transport proteins in the
867 islet b-cells when compared with other tissue cells, the islet b-cells are more likely to
868 accumulate iron. Excessive levels of iron might induce excessive oxidative stress
869 promote islet b-cell apoptosis, and ultimately affect insulin secretion and increase

870 the risk of insulin resistance (123, 124). Circulating levels of key soluble proteins for
871 body iron homeostasis are altered in individuals with obesity, insulin resistance
872 and/or type 2 diabetes mellitus (125). It appears that the intestinal iron availability
873 affects the gut microbiome, which in turns plays a central role in the absorption of
874 iron in the intestine and bacteria-derived metabolites. This two-way interaction
875 between iron homeostasis and the gut microbiota affects systemic glucose
876 metabolism (126). The observation that important iron-processing orthologs are
877 significantly overexpressed in the Sugar Shift-treated group seems to suggest that
878 this formulation alleviates insulin resistance by promoting iron homeostasis via
879 promotion of a “healthier” microbiome.

880 The high relative abundance of ortholog gene K22317 (acyl-CoA:acyl-CoA alkyl
881 transferase) in Sugar Shift-treated individuals is noteworthy as this gene is involved
882 in the regulation of lipid metabolism and subsequent lipid transformation.(127). This
883 process was discussed above in relation to cholesterol levels in Sugar Shift-treated
884 individuals.

885 **Conclusions**

886 Sugar Shift is a symbiotic formulation consisting of a sustainable bacterial guild that
887 promotes the conversion of glucose and fructose to mannitol and promotes the
888 production SSFAs acetate and butyrate. The results indicated that consumption of
889 Sugar Shift twice daily for 12 weeks, in conjunction with standard of medical care for
890 T2DM (72) improves biomarkers for T2DM, including, HOMA-IR index and serum
891 Insulin and LPS levels.

- 892 1. Fasting glucose and HbA1c levels were stabilized during the course of the
893 study, showing a progressive improvement over the course of the study.
- 894 2. In this study it was shown that supplemental treatment of T2DM with Sugar
895 Shift increases alpha diversity of the gut microbiome, which has been
896 associated with a reduction of the biomarkers of T2DM (128, 129).
- 897 3. Insulin resistance was significantly improved in patients treated with Sugar
898 Shift as compared to the Placebo group. The mechanism hypothesized
899 included the modification of the gut microbiota with the concomitant
900 reduction of serum LPS.
- 901 4. Inflammation biomarkers, specifically serum LPS was decreased. It was
902 hypothesized that an increase in the butyrate-producing bacteria and
903 Bifidobacteria were instrumental in the reduction of the inflammatory
904 biomarkers.
- 905 5. Based on the presumed mode of action, that is reducing inflammation by
906 lowering LPS and increasing production of butyrate, it is anticipated that this
907 formulation might be effective in relieving the signs and symptoms of other
908 inflammatory-based intestinal dysbioses.

909 In conclusion, Sugar Shift in this study, was shown to be a suitable nutritional
910 supplement for the control of T2DM and the reduction of biomarkers associated with
911 this dysbiosis

912

913 **Acknowledgments**

914 We would like to express our gratitude to Dr. Miguel H. Estévez del Toro, Director of
915 the Hermanos Ameijeiras Hospital and to Yurailis Reyes, Eng. For their support in
916 initiating and conducting the study.

917

918 This work was supported by The BioCollective, LLC.

919

920 **References Cited**

- 921 1. Sharma S, Tripathi P. Gut microbiome and type 2 diabetes: where we are and
922 where to go? *The Journal of Nutritional Biochemistry*. 2019;63:101-8.
- 923 2. Corrigendum to: 2019 ESC Guidelines on diabetes, pre-diabetes, and
924 cardiovascular diseases developed in collaboration with the EASD. *Eur Heart*
925 *J* [Internet]. 2020 Dec 1; 41(45):[4317 p.].
- 926 3. MINSAP. Anuario Estadístico de Salud 2019
- 927 4. Singer-Englar T, Barlow G, Mathur R. Obesity, diabetes, and the gut
928 microbiome: an updated review. *Expert Review of Gastroenterology &*
929 *Hepatology*. 2019;13(1):3-15.
- 930 5. Xourgia E, Papazafiropoulou A, Papanas N, Melidonis A. Anti-diabetic
931 treatment leads to changes in gut microbiome. *Frontiers in bioscience*
932 (Landmark edition). 2019;24(4):688-99.
- 933 6. Mailing LJ, Allen JM, Buford TW, Fields CJ, Woods JA. Exercise and the Gut
934 Microbiome: A Review of the Evidence, Potential Mechanisms, and
935 Implications for Human Health. *Exercise and Sport Sciences Reviews*.
936 2019;47(2).
- 937 7. Merkevičius K, Kundelis R, Maleckas A, Veličkienė D. Microbiome Changes
938 after Type 2 Diabetes Treatment: A Systematic Review. 2021;57(10):1084.

- 939 8. Chatterjee S, Khunti K, Davies MJ. Type 2 diabetes. *The lancet*.
940 2017;389(10085):2239-51.
- 941 9. Scheen AJ. Pathophysiology of type 2 diabetes. *Acta Clinica Belgica*.
942 2003;58(6):335-41.
- 943 10. Milardi D, Gazit E, Radford SE, Xu Y, Gallardo RU, Caflisch A, et al.
944 Proteostasis of islet amyloid polypeptide: A molecular perspective of risk
945 factors and protective strategies for type II diabetes. *Chemical Reviews*.
946 2021;121(3):1845-93.
- 947 11. Kumari R, Sanjukta S, Sahoo D, Rai AK. Functional peptides in Asian protein
948 rich fermented foods: production and health benefits. *Systems Microbiology*
949 *and Biomanufacturing*. 2021:1-13.
- 950 12. Kumari R, Yadav Y, Misra R, Das U, Adhikari UD, Malakar P, et al. Emerging
951 frontiers of antibiotics use and their impacts on the human gut microbiome.
952 *Microbiological Research*. 2022:127127.
- 953 13. Bellary S, Kyrou I, Brown JE, Bailey CJ. Type 2 diabetes mellitus in older
954 adults: clinical considerations and management. *Nature Reviews*
955 *Endocrinology*. 2021;17(9):534-48.
- 956 14. Jonas W, Schürmann A. Genetic and epigenetic factors determining NAFLD
957 risk. *Molecular Metabolism*. 2021;50:101111.

- 958 15. Arora A, Behl T, Sehgal A, Singh S, Sharma N, Bhatia S, et al. Unravelling the
959 involvement of gut microbiota in type 2 diabetes mellitus. *Life sciences*.
960 2021;273:119311.
- 961 16. Corb Aron RA, Abid A, Vesa CM, Nechifor AC, Behl T, Ghitea TC, et al.
962 Recognizing the Benefits of Pre-/Probiotics in Metabolic Syndrome and Type
963 2 Diabetes Mellitus Considering the Influence of *Akkermansia muciniphila* as a
964 Key Gut Bacterium. *Microorganisms*. 2021;9(3).
- 965 17. Rodrigues RR, Gurung M, Li Z, García-Jaramillo M, Greer R, Gaulke C, et al.
966 Transkingdom interactions between *Lactobacilli* and hepatic mitochondria
967 attenuate western diet-induced diabetes. *Nature communications*.
968 2021;12(1):1-15.
- 969 18. De Bernardini N, Basile A, Zampieri G, Kovalovszki A, De Diego Diaz B, Offer
970 E, et al. Integrating metagenomic binning with flux balance analysis to unravel
971 syntrophies in anaerobic CO₂ methanation. *Microbiome*. 2022;10(1):1-18.
- 972 19. Colarusso AV, Goodchild-Michelman I, Rayle M, Zomorodi AR.
973 Computational modeling of metabolism in microbial communities on a
974 genome-scale. *Current Opinion in Systems Biology*. 2021;26:46-57.
- 975 20. Calin MR KS, Sangwan N, Cano RJ. (Inventors) inventor Probiotics and
976 Methods of use. USA2019.

- 977 21. Circu ML, Aw TY. Redox biology of the intestine. *Free Radic Res.* 2011;45(11-
978 12):1245-66.
- 979 22. Cañete R. The Cuban Public Health System Focuses Research on Community
980 Needs. *Current Therapeutic Research.* 2017;85:1.
- 981 23. Shoelson SE, Lee J, Goldfine AB. Inflammation and insulin resistance. *The*
982 *Journal of clinical investigation.* 2006;116(7):1793-801.
- 983 24. Li H-Y, Zhou D-D, Gan R-Y, Huang S-Y, Zhao C-N, Shang A, et al. Effects
984 and mechanisms of probiotics, prebiotics, synbiotics, and postbiotics on
985 metabolic diseases targeting gut microbiota: a narrative review. *Nutrients.*
986 2021;13(9):3211.
- 987 25. World Medical A. Declaration of Helsinki–Ethical Principles for Medical
988 Research Involving Human Subjects [Internet]; 2018. 2021.
- 989 26. Petersmann A, Müller-Wieland D, Müller UA, Landgraf R, Nauck M,
990 Freckmann G, et al. Definition, Classification and Diagnosis of Diabetes
991 Mellitus. *Exp Clin Endocrinol Diabetes* [Internet]. 2019 20.12.2019; 127(S
992 01):[S1-S7 pp.].
- 993 27. Yoon S-H, Ha S-M, Kwon S, Lim J, Kim Y, Seo H, et al. Introducing
994 EzBioCloud: a taxonomically united database of 16S rRNA gene sequences
995 and whole-genome assemblies. *International journal of systematic and*
996 *evolutionary microbiology.* 2017;67(5):1613.

- 997 28. Lee B, Moon T, Yoon S, Weissman T. DUDE-Seq: fast, flexible, and robust
998 denoising for targeted amplicon sequencing. PloS one. 2017;12(7):e0181463.
- 999 29. Edgar RC, Haas BJ, Clemente JC, Quince C, Knight R. UCHIME improves
1000 sensitivity and speed of chimera detection. Bioinformatics. 2011;27(16):2194-
1001 200.
- 1002 30. Edgar R. Usearch. Lawrence Berkeley National Lab.(LBNL), Berkeley, CA
1003 (United States); 2010.
- 1004 31. Edgar RC. UPARSE: highly accurate OTU sequences from microbial amplicon
1005 reads. Nature methods. 2013;10(10):996-8.
- 1006 32. Prasad DV, Madhusudanan S, Jaganathan S. uCLUST-a new algorithm for
1007 clustering unstructured data. ARPN Journal of Engineering and Applied
1008 Sciences. 2015;10(5):2108-17.
- 1009 33. Douglas GM, Maffei VJ, Zaneveld JR, Yurgel SN, Brown JR, Taylor CM, et al.
1010 PICRUSt2 for prediction of metagenome functions. Nature biotechnology.
1011 2020;38(6):685-8.
- 1012 34. Kanehisa M, Goto S. KEGG: kyoto encyclopedia of genes and genomes.
1013 Nucleic acids research. 2000;28(1):27-30.
- 1014 35. Mann HB, Whitney DR. On a test of whether one of two random variables is
1015 stochastically larger than the other. The annals of mathematical statistics.
1016 1947:50-60.

- 1017 36. Bray JR, Curtis JT. An ordination of upland forest communities of southern
1018 Wisconsin. *Ecological Monographs* (27). PRIMER-E Plymouth; 1957. p. 325-
1019 49.
- 1020 37. Lozupone CA, Stombaugh JI, Gordon JI, Jansson JK, Knight RJN. Diversity,
1021 stability and resilience of the human gut microbiota. *2012;489(7415):220-30.*
- 1022 38. Anderson MJ. A new method for non-parametric multivariate analysis of
1023 variance. *Austral ecology*. 2001;26(1):32-46.
- 1024 39. Daniel WW. Kruskal–Wallis one-way analysis of variance by ranks. *Applied*
1025 *nonparametric statistics*. 1990:226-34.
- 1026 40. Segata N, Izard J, Waldron L, Gevers D, Miropolsky L, Garrett WS, et al.
1027 Metagenomic biomarker discovery and explanation. *Genome biology*.
1028 2011;12(6):1-18.
- 1029 41. Segata N, Waldron L, Ballarini A, Narasimhan V, Jousson O, Huttenhower C.
1030 Metagenomic microbial community profiling using unique clade-specific
1031 marker genes. *Nature methods*. 2012;9(8):811-4.
- 1032 42. Massey Jr FJJotAsA. The Kolmogorov-Smirnov test for goodness of fit.
1033 1951;46(253):68-78.
- 1034 43. F.R.S. KPJPMS. X. On the criterion that a given system of deviations from the
1035 probable in the case of a correlated system of variables is such that it can be
1036 reasonably supposed to have arisen from random sampling. *2009;50:157-75.*

- 1037 44. Student. The probable error of a mean. *Biometrika*. 1908:1-25.
- 1038 45. Friedman MJ. The use of ranks to avoid the assumption of normality
1039 implicit in the analysis of variance. 1937;32(200):675-701.
- 1040 46. Rosner B, Glynn RJ, Lee MLTJB. The Wilcoxon signed rank test for paired
1041 comparisons of clustered data. 2006;62(1):185-92.
- 1042 47. Jones DH. Book Review: *Statistical Methods*, 8th Edition George W.
1043 Snedecor and William G. Cochran Ames: Iowa State University Press, 1989.
1044 xix + 491 pp. 1994;19(3):304-7.
- 1045 48. Wickens TD, Keppel G. *Design and analysis: A researcher's handbook*:
1046 Pearson Prentice-Hall Upper Saddle River, NJ; 2004.
- 1047 49. Shannon CE. A mathematical theory of communication. *ACM SIGMOBILE*
1048 mobile computing and communications review. 2001;5(1):3-55.
- 1049 50. Chao A. Nonparametric estimation of the number of classes in a population.
1050 *Scandinavian Journal of statistics*. 1984:265-70.
- 1051 51. Good IJ. The population frequencies of species and the estimation of
1052 population parameters. *Biometrika*. 1953;40(3-4):237-64.
- 1053 52. Cox MAA, Cox TF. Multidimensional scaling. *Handbook of data visualization*:
1054 Springer; 2008. p. 315-47.

- 1055 53. Jaccard P. Étude comparative de la distribution florale dans une portion des
1056 Alpes et des Jura. Bull Soc Vaudoise Sci Nat. 1901;37:547-79.
- 1057 54. Fukunaga K. Introduction to statistical pattern recognition: Elsevier; 2013.
- 1058 55. Robertson DS, Wildenhain J, Javanmard A, Karp NA. onlineFDR: an R
1059 package to control the false discovery rate for growing data repositories.
1060 Bioinformatics. 2019;35(20):4196-9.
- 1061 56. Bostom AG, Kronenberg F, Ritz E. Predictive performance of renal function
1062 equations for patients with chronic kidney disease and normal serum
1063 creatinine levels. Journal of the American Society of Nephrology.
1064 2002;13(8):2140-4.
- 1065 57. Finney H, Newman DJ, Price CP. Adult reference ranges for serum cystatin C,
1066 creatinine and predicted creatinine clearance. Annals of clinical biochemistry.
1067 2000;37(1):49-59.
- 1068 58. Thiagarajan P, Parker CJ, Prchal JT. How do red blood cells die? Frontiers in
1069 Physiology. 2021;12:655393.
- 1070 59. Pearson K. X. On the criterion that a given system of deviations from the
1071 probable in the case of a correlated system of variables is such that it can be
1072 reasonably supposed to have arisen from random sampling. The London,
1073 Edinburgh, and Dublin Philosophical Magazine and Journal of Science.
1074 1900;50(302):157-75.

- 1075 60. Andrews S. FastQC: a quality control tool for high throughput sequence data.
1076 Babraham Bioinformatics, Babraham Institute, Cambridge, United Kingdom;
1077 2010.
- 1078 61. Rosner B, Glynn RJ, Lee MLT. The Wilcoxon signed rank test for paired
1079 comparisons of clustered data. *Biometrics*. 2006;62(1):185-92.
- 1080 62. Sokal RR. A statistical method for evaluating systematic relationships. *Univ*
1081 *Kansas, Sci Bull*. 1958;38:1409-38.
- 1082 63. Yin Y, Wang J. Predictive functional profiling of microbial communities in
1083 fermentative hydrogen production system using PICRUSt. *International*
1084 *Journal of Hydrogen Energy*. 2021;46(5):3716-25.
- 1085 64. Langille MGI, Zaneveld J, Caporaso JG, McDonald D, Knights D, Reyes JA, et
1086 al. Predictive functional profiling of microbial communities using 16S rRNA
1087 marker gene sequences. *Nature biotechnology*. 2013;31(9):814-21.
- 1088 65. Kocsis T, Molnár B, Németh D, Hegyi P, Szakács Z, Bálint A, et al. Probiotics
1089 have beneficial metabolic effects in patients with type 2 diabetes mellitus: a
1090 meta-analysis of randomized clinical trials. *Scientific Reports*.
1091 2020;10(1):11787.
- 1092 66. Hu Y-m, Zhou F, Yuan Y, Xu Y-c. Effects of probiotics supplement in patients
1093 with type 2 diabetes mellitus: A meta-analysis of randomized trials. *Medicina*
1094 *Clínica (English Edition)*. 2017;148(8):362-70.

- 1095 67. Asemi Z, Zare Z, Shakeri H, Sabihi S-s, Esmailzadeh AJAon, metabolism.
1096 Effect of multispecies probiotic supplements on metabolic profiles, hs-CRP,
1097 and oxidative stress in patients with type 2 diabetes. 2013;63(1-2):1-9.
- 1098 68. Mohammad-Shahi M, Veissi M, Haidari F, Shahbazian H, Kaydani G-A,
1099 Mohammadi F. Effects of probiotic yogurt consumption on inflammatory
1100 biomarkers in patients with type 2 diabetes2014 2014/6/30 %J Bioimpacts;
1101 4(2):[83-8 pp.]. Available from:
1102 https://bi.tbzmed.ac.ir/Article/BI_1211_20131009200630.
- 1103 69. Firouzi S, Majid HA, Ismail A, Kamaruddin NA, Barakatun-Nisak M-YJEJon.
1104 Effect of multi-strain probiotics (multi-strain microbial cell preparation) on
1105 glycemic control and other diabetes-related outcomes in people with type 2
1106 diabetes: a randomized controlled trial. 2017;56(4):1535-50.
- 1107 70. Hove KD, Brøns C, Færch K, Lund SS, Rossing P, Vaag A. Effects of 12
1108 weeks of treatment with fermented milk on blood pressure, glucose
1109 metabolism and markers of cardiovascular risk in patients with type 2
1110 diabetes: a randomised double-blind placebo-controlled study. European
1111 Journal of Endocrinology. 2015;172(1):11-20.
- 1112 71. Asemi Z, Alizadeh S-A, Ahmad K, Goli M, Esmailzadeh AJCN. Effects of beta-
1113 carotene fortified synbiotic food on metabolic control of patients with type 2
1114 diabetes mellitus: A double-blind randomized cross-over controlled clinical
1115 trial. 2016;35(4):819-25.

- 1116 72. American Diabetes A. 2. Classification and diagnosis of diabetes: standards
1117 of medical care in diabetes—2021. *Diabetes care*. 2021;44(Supplement
1118 1):S15-S33.
- 1119 73. Cohen RM, Franco RS, Khera PK, Smith EP, Lindsell CJ, Ciraolo PJ, et al.
1120 Red cell life span heterogeneity in hematologically normal people is sufficient
1121 to alter HbA1c. *Blood, The Journal of the American Society of Hematology*.
1122 2008;112(10):4284-91.
- 1123 74. Lew VL, Tiffert T. On the Mechanism of Human Red Blood Cell Longevity:
1124 Roles of Calcium, the Sodium Pump, PIEZO1, and Gardos Channels. (1664-
1125 042X (Print)).
- 1126 75. Scheen AJ. Metformin and COVID-19: From cellular mechanisms to reduced
1127 mortality. *Diabetes & Metabolism*. 2020;46(6):423-6.
- 1128 76. Hamer M, Gale CR, Batty GD. Diabetes, glycaemic control, and risk of
1129 COVID-19 hospitalisation: Population-based, prospective cohort study.
1130 *Metabolism*. 2020;112:154344.
- 1131 77. Caycho-Rodríguez T, Vilca LW, Corrales-Reyes IE, Hernández-García F,
1132 Pérez AP, Quintana PG, et al. COVID-19 contagion concern scale (PRE-
1133 COVID-19): Validation in Cuban patients with type 2 diabetes. *Diabetes &*
1134 *Metabolic Syndrome: Clinical Research & Reviews*. 2021;15(5):102245.
- 1135 78. Rice JA. *Mathematical statistics and data analysis*: Cengage Learning; 2006.

- 1136 79. Isolauri E, Sütas Y, Kankaanpää P, Arvilommi H, Salminen S. Probiotics:
1137 effects on immunity. *The American Journal of Clinical Nutrition*.
1138 2001;73(2):444s-50s.
- 1139 80. Maldonado Galdeano C, Cazorla SI, Lemme Dumit JM, Vélez E, Perdigón G.
1140 Beneficial Effects of Probiotic Consumption on the Immune System. *Annals of*
1141 *Nutrition and Metabolism*. 2019;74(2):115-24.
- 1142 81. Sato J, Kanazawa A, Azuma K, Ikeda F, Goto H, Komiya K, et al. Probiotic
1143 reduces bacterial translocation in type 2 diabetes mellitus: A randomised
1144 controlled study. 2017;7(1):1-10.
- 1145 82. Madempudi RS, Ahire JJ, Neelamraju J, Tripathi A, Nanal S. Efficacy of
1146 UB0316, a multi-strain probiotic formulation in patients with type 2 diabetes
1147 mellitus: A double blind, randomized, placebo controlled study. *PLOS ONE*.
1148 2019;14(11):e0225168.
- 1149 83. Nesti L, Mengozzi A, Tricò D. Impact of nutrient type and sequence on
1150 glucose tolerance: physiological insights and therapeutic implications.
1151 *Frontiers in Endocrinology*. 2019;10:144.
- 1152 84. Dimitriadis GD, Maratou E, Kountouri A, Board M, Lambadiari V. Regulation of
1153 postabsorptive and postprandial glucose metabolism by insulin-dependent
1154 and insulin-independent mechanisms: an integrative approach. *Nutrients*.
1155 2021;13(1):159.

- 1156 85. Gérard C, Vidal H. Impact of gut microbiota on host glycemic control.
1157 Frontiers in endocrinology. 2019;10:29.
- 1158 86. Carlin MR, Kazemi,S.K., Sangwan,N., Cano,R.J., inventorProbiotics and
1159 Methos of Use. USA patent WO2019/113023A9. 2019 05.12.2019
- 1160 87. Salvi PS, Cowles RA. Butyrate and the Intestinal Epithelium: Modulation of
1161 Proliferation and Inflammation in Homeostasis and Disease. LID -
1162 10.3390/cells10071775 [doi] LID - 1775. (2073-4409 (Electronic)).
- 1163 88. Sivamaruthi BS, Fern LA, Rashidah Pg Hj Ismail DSN, Chaiyasut C. The
1164 influence of probiotics on bile acids in diseases and aging. Biomedicine &
1165 Pharmacotherapy. 2020;128:110310.
- 1166 89. Liong MT, Shah NP. Acid and Bile Tolerance and Cholesterol Removal Ability
1167 of Lactobacilli Strains. Journal of Dairy Science. 2005;88(1):55-66.
- 1168 90. Lye HS, Rusul G, Liong MT. Removal of cholesterol by lactobacilli via
1169 incorporation and conversion to coprostanol. Journal of Dairy Science.
1170 2010;93(4):1383-92.
- 1171 91. Wang C, Li S, Xue P, Yu L, Tian F, Zhao J, et al. The effect of probiotic
1172 supplementation on lipid profiles in adults with overweight or obesity: A meta-
1173 analysis of randomized controlled trials. Journal of Functional Foods.
1174 2021;86:104711.

- 1175 92. Salamone D, Rivellese AA, Vetrani C. The relationship between gut
1176 microbiota, short-chain fatty acids and type 2 diabetes mellitus: the possible
1177 role of dietary fibre. *Acta Diabetologica*. 2021;58(9):1131-8.
- 1178 93. Chomani S. The effect of exercise training at different intensities on blood
1179 glucose regulation and cardiorespiratory fitness in patients with Type 2
1180 Diabetes: a randomized controlled trial. *VIREF Revista de Educación Física*.
1181 2021;10(4):148-57.
- 1182 94. Kim YA, Keogh JB, Clifton PM. Probiotics, prebiotics, synbiotics and insulin
1183 sensitivity. *Nutrition Research Reviews*. 2018;31(1):35-51.
- 1184 95. Chen Z, Radjabzadeh D, Chen L, Kurilshikov A, Kavousi M, Ahmadizar F, et
1185 al. Association of insulin resistance and type 2 diabetes with gut microbial
1186 diversity: a microbiome-wide analysis from population studies.
1187 2021;4(7):e2118811-e.
- 1188 96. Petersen MC, Shulman GI. Mechanisms of Insulin Action and Insulin
1189 Resistance. 2018;98(4):2133-223.
- 1190 97. Sesti G. Pathophysiology of insulin resistance. *Best practice & research*
1191 *Clinical endocrinology & metabolism*. 2006;20(4):665-79.
- 1192 98. Samuel VT, Shulman GI. The pathogenesis of insulin resistance: integrating
1193 signaling pathways and substrate flux. *The Journal of clinical investigation*.
1194 2016;126(1):12-22.

- 1195 99. Chen L, Chen R, Wang H, Liang F. Mechanisms linking inflammation to insulin
1196 resistance. *International journal of endocrinology*. 2015;2015.
- 1197 100. Jang HR, Lee H-YJWJoD. Mechanisms linking gut microbial metabolites to
1198 insulin resistance. 2021;12(6):730.
- 1199 101. Schertzer JD, Lam TKJAJp-E, *Metabolism*. Peripheral and central regulation
1200 of insulin by the intestine and microbiome. *American Physiological Society*
1201 Rockville, MD; 2021. p. E234-E9.
- 1202 102. Chen Z, Radjabzadeh D, Chen L, Kurilshikov A, Kavousi M, Ahmadizar F, et
1203 al. Association of Insulin Resistance and Type 2 Diabetes With Gut Microbial
1204 Diversity: A Microbiome-Wide Analysis From Population Studies. (2574-3805
1205 (Electronic)).
- 1206 103. Zouiouich S, Lofffield E, Huybrechts I, Viallon V, Louca P, Vogtmann E, et al.
1207 Markers of metabolic health and gut microbiome diversity: findings from two
1208 population-based cohort studies. *Diabetologia*. 2021;64(8):1749-59.
- 1209 104. Salguero MV, Al-Obaide MAI, Singh R, Siepmann T, Vasylyeva TL. Dysbiosis
1210 of Gram-negative gut microbiota and the associated serum
1211 lipopolysaccharide exacerbates inflammation in type 2 diabetic patients with
1212 chronic kidney disease. *Experimental and therapeutic medicine*.
1213 2019;18(5):3461-9.

- 1214 105. Cani PD, Osto M, Geurts L, Everard A. Involvement of gut microbiota in the
1215 development of low-grade inflammation and type 2 diabetes associated with
1216 obesity. *Gut microbes*. 2012;3(4):279-88.
- 1217 106. Snelson M, de Pasquale C, Ekinici EI, Coughlan MT. Gut microbiome,
1218 prebiotics, intestinal permeability and diabetes complications. *Best Practice &
1219 Research Clinical Endocrinology & Metabolism*. 2021;35(3):101507.
- 1220 107. Candelli M, Franza L, Pignataro G, Ojetti V, Covino M, Piccioni A, et al.
1221 Interaction between Lipopolysaccharide and Gut Microbiota in Inflammatory
1222 Bowel Diseases. *International Journal of Molecular Sciences* [Internet]. 2021;
1223 22(12).
- 1224 108. Turnbaugh PJ, Ley RE, Hamady M, Fraser-Liggett CM, Knight R, Gordon JI.
1225 The Human Microbiome Project. *Nature*. 2007;449(7164):804-10.
- 1226 109. Proctor LM, Creasy HH, Fettweis JM, Lloyd-Price J, Mahurkar A, Zhou W, et
1227 al. The Integrative Human Microbiome Project. *Nature*. 2019;569(7758):641-8.
- 1228 110. Ehrlich SD, Meta HITC. MetaHIT: The European Union Project on
1229 metagenomics of the human intestinal tract. *Metagenomics of the human
1230 body*: Springer; 2011. p. 307-16.
- 1231 111. Vacca M, Celano G, Calabrese FM, Portincasa P, Gobbetti M, De Angelis M.
1232 The Controversial Role of Human Gut Lachnospiraceae. 2020;8(4):573.

- 1233 112. Gao J, Guo X, Wei W, Li R, Hu K, Liu X, et al. The association of fried meat
1234 consumption with the gut microbiota and fecal metabolites and its impact on
1235 glucose homoeostasis, intestinal endotoxin levels, and systemic inflammation:
1236 a randomized controlled-feeding trial. *Diabetes Care*. 2021;44(9):1970-9.
- 1237 113. Esgalhado M, Kemp JA, Damasceno NR, Fouque D, Mafra DJFm. Short-chain
1238 fatty acids: A link between prebiotics and microbiota in chronic kidney
1239 disease. 2017;12(15):1413-25.
- 1240 114. Sun M, Wu W, Liu Z, Cong YJJog. Microbiota metabolite short chain fatty
1241 acids, GPCR, and inflammatory bowel diseases. 2017;52(1):1-8.
- 1242 115. Portune KJ, Benítez-Páez A, Del Pulgar EMG, Cerrudo V, Sanz YJMn,
1243 research f. Gut microbiota, diet, and obesity-related disorders—The good, the
1244 bad, and the future challenges. 2017;61(1):1600252.
- 1245 116. Orsso CE, Peng Y, Deehan EC, Tan Q, Field CJ, Madsen KL, et al.
1246 Composition and Functions of the Gut Microbiome in Pediatric Obesity:
1247 Relationships with Markers of Insulin Resistance. 2021;9(7):1490.
- 1248 117. Gurung M, Li Z, You H, Rodrigues R, Jump DB, Morgun A, et al. Role of gut
1249 microbiota in type 2 diabetes pathophysiology. (2352-3964 (Electronic)).
- 1250 118. Qian XA-O, Si Q, Lin G, Zhu M, Lu J, Zhang H, et al. *Bifidobacterium*
1251 *adolescentis* Is Effective in Relieving Type 2 Diabetes and May Be Related to

- 1252 Its Dominant Core Genome and Gut Microbiota Modulation Capacity. LID -
1253 10.3390/nu14122479 [doi] LID - 2479. (2072-6643 (Electronic)).
- 1254 119. Laursen MA-O, Laursen RP, Larnkjær A, Mølgaard C, Michaelsen KF, Frøkiær
1255 H, et al. Faecalibacterium Gut Colonization Is Accelerated by Presence of
1256 Older Siblings. LID - 10.1128/mSphere.00448-17 [doi] LID - e00448-17.
1257 (2379-5042 (Print)).
- 1258 120. Parsaei M, Sarafraz N, Moaddab SY, Ebrahimzadeh Leylabadlo H. The
1259 importance of Faecalibacterium prausnitzii in human health and diseases.
1260 (2052-2975 (Print)).
- 1261 121. Sokol H, Pigneur B, Watterlot L, Lakhdari O, Bermúdez-Humarán LG,
1262 Gratadoux J-J, et al. Faecalibacterium prausnitzii is an anti-inflammatory
1263 commensal bacterium identified by gut microbiota analysis of Crohn disease
1264 patients. Proceedings of the National Academy of Sciences.
1265 2008;105(43):16731-6.
- 1266 122. Zhang S, Zhao J, Xie F, He H, Johnston LJ, Dai X, et al. Dietary fiber-derived
1267 short-chain fatty acids: A potential therapeutic target to alleviate
1268 obesity-related nonalcoholic fatty liver disease. Obesity Reviews.
1269 2021;22(11):e13316.

- 1270 123. Liu J, Li Q, Yang Y, Ma L. Iron metabolism and type 2 diabetes mellitus: A
1271 meta-analysis and systematic review. *Journal of diabetes investigation*.
1272 2020;11(4):946-55.
- 1273 124. Fernández-Real JM, McClain D, Manco M. Mechanisms linking glucose
1274 homeostasis and iron metabolism toward the onset and progression of type 2
1275 diabetes. *Diabetes care*. 2015;38(11):2169-76.
- 1276 125. Cartron ML, Maddocks S, Gillingham P, Craven CJ, Andrews SC. Feo –
1277 Transport of Ferrous Iron into Bacteria. *Biometals*. 2006;19(2):143-57.
- 1278 126. Mayneris-Perxachs J, Moreno-Navarrete JM, Fernández-Real JM. The role of
1279 iron in host–microbiota crosstalk and its effects on systemic glucose
1280 metabolism. *Nature Reviews Endocrinology*. 2022.
- 1281 127. Ruggles KV, Turkish A, Sturley SLJAron. Making, baking, and breaking: the
1282 synthesis, storage, and hydrolysis of neutral lipids. 2013:413-51.
- 1283 128. Liu T, Chen X, Xu Y, Wu W, Tang W, Chen Z, et al. Gut microbiota partially
1284 mediates the effects of fine particulate matter on type 2 diabetes: Evidence
1285 from a population-based epidemiological study. *Environment International*.
1286 2019;130:104882.
- 1287 129. Maskarinec G, Raquinio P, Kristal BS, Setiawan VW, Wilkens LR, Franke AA,
1288 et al. The gut microbiome and type 2 diabetes status in the Multiethnic
1289 Cohort. *Plos one*. 2021;16(6):e0250855.



CONSORT

TRANSPARENT REPORTING of TRIALS

CONSORT 2010 Flow Diagram




Figure 1

BiotiQuest™ Sugar Shift Clinical Study Design






Figure 2

Fasting Glucose



Postprandial Glucose - 2 h




(a) —●— Placebo —●— Sugar Shift Linear (Placebo) Linear (Sugar Shift)


(b) —●— Placebo —●— Sugar Shift Linear (Placebo) Linear (Sugar Shift)

Figure 3


Insulin Resistance: Day 1



Insulin Resistance: Control Group



Insulin Resistance: Day 84



Insulin Resistance: Treated Group




Figure 4

Serum LPS






Figure 5

Alpha Diversity: Day 1



Alpha Diversity: Control Group



Alpha Diversity: Treatment Group




Figure 6